Synairgen began a placebo-controlled Phase 2 trial in COVID-19 patients in the UK in March 2020. Based on the results of the Phase 2 trial, the company initiated a Phase 3 trial in January 2021 which ultimately included 17 countries.
Read more about SG018 at clinicaltrials.gov
Synairgen reported topline results of SPRINTER (SG018) in February 2022, and a more detailed full analysis including post hoc analyses at the ATS International Conference in May 2022.
In September 2022, Synairgen announced positive findings from the analysis of data from 60 and 90-day follow-up visits (Long COVID) from SG018.